Evommune, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Evommune, Inc. (NYSE: EVMN) is a clinical-stage biotechnology company that discovers and develops innovative oral therapies targeting key drivers of chronic inflammatory diseases, including mast cell, sensory neuron, and T-cell activity. Founded in 2020 and headquartered in Palo Alto, California, the company advances a pipeline of differentiated product candidates, with lead program EVO756, a potent and highly selective small-molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), in Phase 2b development for chronic spontaneous urticaria (CSU) and Phase 2 for chronic inducible urticaria (CIndU) and atopic dermatitis (AD); EVO301, an IL-18 targeted fusion protein, in development for AD and ulcerative colitis (UC); and additional preclinical programs for broader immune-mediated inflammatory conditions. Evommune operates primarily in the United States, focusing on patients with unmet needs in dermatology and gastroenterology segments where current therapies often provide symptomatic relief without addressing disease progression. In October 2024, Evommune completed a $115 million Series C financing co-led by RA Capital Management and Sectoral Asset Management to advance EVO756 and EVO301 clinical programs, including multiple Phase 2 data readouts expected in 2025 and 2026, and reported positive proof-of-concept data for EVO756 with full results presented in Q4 2024. In 2024, the company acquired EVO301 from South Korean biotech AprilBio for $15 million upfront and initiated a Phase 2b trial of EVO756 in moderate-to-severe CSU, which is Phase 3-enabling with data anticipated in mid-2026. Most recently, in November 2025, Evommune closed a $150 million initial public offering on the New York Stock Exchange, with full exercise of underwriters' option for additional shares, providing capital to fund ongoing clinical trials, expand discovery research, and support regulatory milestones.
Company News
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evommune Halts Atopic Dermatitis Program Following Trial Failure
Evommune scraps eczema drug after trial miss, shares plunge
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Brokerages Set Evommune, Inc. (NYSE:EVMN) PT at $43.25
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky
Evommune's Healthy Balance Sheet Buys Them Time For AD
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Evommune's Skin Disorder Study Falls Short
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade